A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy by Lee, C P et al.
A phase I study of the nitroimidazole hypoxia marker SR4554
using
19F magnetic resonance spectroscopy
CP Lee
1, GS Payne
1, A Oregioni
1, R Ruddle
1, S Tan
1, FI Raynaud
1, D Eaton
1, MJ Campbell
2, K Cross
2,
G Halbert
3, M Tracy
4, J McNamara
4, B Seddon
1, MO Leach
1, P Workman*,1 and I Judson
1
1Cancer Research UK Centre for Cancer Therapeutics, Cancer Research UK Clinical Magnetic Resonance Research Group and Section of Medicine,
The Institute of Cancer Research and Drug Development Unit, The Royal Marsden Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK;
2Drug
Development Office, Cancer Research UK, 61 Lincoln’s Inn Fields, London WC2A 3PX, UK;
3Cancer Research UK Formulation Unit, Strathclyde Institute
of Pharmacy and Biomedical Sciences, Royal College Building, University of Strathclyde, 204 George Street, Glasgow G1 1XW, UK;
4SRI International, 333
Ravenswood Avenue, Menlo Park, California 94025, USA
BACKGROUND: SR4554 is a fluorine-containing 2-nitroimidazole, designed as a hypoxia marker detectable with
19F magnetic resonance
spectroscopy (MRS). In an initial phase I study of SR4554, nausea/vomiting was found to be dose-limiting, and 1400mgm
 2 was
established as MTD. Preliminary MRS studies demonstrated some evidence of
19F retention in tumour. In this study we investigated
higher doses of SR4554 and intratumoral localisation of the
19F MRS signal.
METHODS: Patients had tumours X3cm in diameter and p4cm deep. Measurements were performed using
1H/
19F surface coils
and localised
19F MRS acquisition. SR4554 was administered at 1400mgm
 2, with subsequent increase to 2600mgm
 2
using prophylactic metoclopramide. Spectra were obtained immediately post infusion (MRS no. 1), at 16h (MRS no. 2) and 20h
(MRS no. 3), based on the SR4554 half-life of 3.5h determined from a previous study.
19Fluorine retention index (%) was defined as
(MRS no. 2/MRS no. 1)*100.
RESULTS: A total of 26 patients enrolled at: 1400 (n¼16), 1800 (n¼1), 2200 (n¼1) and 2600mgm
 2 (n¼8). SR4554 was well
tolerated and toxicities were all pgrade 1; mean plasma elimination half-life was 3.7±0.9h. SR4554 signal was seen on both
unlocalised and localised MRS no. 1 in all patients. Localised
19F signals were detected at MRS no. 2 in 5 out of 9 patients and 4 out of
5 patients at MRS no. 3. The mean retention index in tumour was 13.6 (range 0.6–43.7) compared with 4.1 (range 0.6–7.3) for
plasma samples taken at the same times (P¼0.001) suggesting
19F retention in tumour and, therefore, the presence of hypoxia.
CONCLUSION: We have demonstrated the feasibility of using
19F MRS with SR4554 as a potential method of detecting hypoxia. Certain
patients showed evidence of
19F retention in tumour, supporting further development of this technique for detection of tumour
hypoxia.
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Nitroimidazoles were initially developed as radiosensitising agents
and later as cytotoxins for hypoxic cells. There is also interest in
their use as hypoxia markers (Chapman, 1991; Hodgkiss, 1998).
This is based on the ability of nitroimidazoles to undergo selective
bioreductive metabolism by nitroreductases under hypoxic con-
ditions to reactive intermediates, which then become covalently
bound to macromolecules within the cell (Wardman, 1977;
Varghese and Whitmore, 1980). These adducts are retained within
the hypoxic cells for longer periods of time as compared with the
parent compound (Chapman et al, 1981; Miller et al, 1982), which
forms the basis for detection of bioreduced nitroimidazoles in
hypoxic cells. The side chain of the imidazole ring also becomes
bound in hypoxic cells (Raleigh et al, 1985); thus labelling of the
side chain with an appropriate isotope or immunologically
recognisable marker allows the bioreduced compound to be
detected, indicating the presence of hypoxia.
SR4554 is a 2-nitroimidazole that has been rationally designed
for use as a non-invasive probe of tumour hypoxia (Aboagye et al,
1995b, 1997a,b, 1998a,b). The key properties introduced to
produce the desired chemical and pharmacokinetic properties
for a hypoxia marker are (1) a nitro group with the appropriate
reduction potential for hypoxia-dependent nitroreduction; (2)
amide and hydroxyl substituents in the side chain designed to
increase hydrophilicity, resulting in increased water solubility,
rapid renal excretion and reduced central nervous penetration and
hence toxicity; and (3) three magnetically equivalent fluorine
atoms to increase the sensitivity of detection by
19F magnetic
resonance spectroscopy (MRS).
Extensive preclinical studies have validated the use of SR4554 as
a hypoxia marker. In preclinical tumour models, for which plasma
half-life was 37min (Seddon et al, 2002), the 3-h
19F retention
index (
19F-RI), defined as the ratio of total SR4554 tissue
concentration (determined by MRS) at 3h divided by that at an
early time point (0.75–1h) after administration of SR4554,
expressed as a percentage, was found to correlate well with pO2
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svalues measured by the polarographic electrode (Seddon et al,
2002). Thus, the 3-h
19F-RI was thought to be a good measure of
retained SR4554 bioreduction products and therefore of hypoxia
in these models. The
19F-RI was also shown to correlate with the
intrinsic radiobiological hypoxic fraction of several mouse
tumours (Seddon et al, 2002). Furthermore, in experiments using
oxygen-modifying agents such as hydralazine, combretastatin or
carbogenþnicotinamide, the change in the 3-h
19F-RI was shown
to correlate very closely with changes in pO2 values determined
using Eppendorf probes (Seddon et al, 2002).
These promising preclinical data led to the commencement of
a phase I safety study of SR4554 in patients with advanced
malignancies, in 2000, under the auspices of Cancer Research UK.
This study enrolled eight patients and reported nausea and
vomiting as dose-limiting toxicities (DLTs) at a dose of
1600mgm
 2 (Seddon et al, 2003). No other toxicities were
observed. Pharmacokinetic studies demonstrated a short plasma
half-life (3.45±0.62h), rapid plasma clearance (12.6±3.4lh
 1)
and high renal excretion (87.4±8.6%), the ideal profile for a
hypoxia marker (Seddon et al, 2003). Preliminary MRS studies of
three of these patients showed promising results, with some
evidence of
19F retention.
This study was therefore continued, and we now report further
data obtained from this phase I study of SR4554 using
19F MRS.
The primary aim of this part of the study was to further
investigate
19F MRS to develop a reliable parameter of SR4554
retention in tumour that could be used as a potential surrogate
measure of tumour hypoxia. This involved the correlation of
tumour
19F signal with plasma SR4554 levels and of the necessity
achieving a dose of SR4554 capable of producing a
19F signal of
sufficient intensity to be reliably detected by localised MRS.
Variable success at the dose defined by the initial safety study led
to a limited further dose escalation of SR4554 made possible by
administration of a prophylactic antiemetic. Both unlocalised and
localised spectroscopy were investigated.
MATERIALS AND METHODS
Study design
This was a single-centre, phase I study conducted under the
auspices of Cancer Research UK. The study protocol was approved
by the Cancer Research UK Internal Review Board and by the
Royal Marsden Hospital Ethics Committee and Committee for
Clinical Research.
All patients had a baseline dynamic contrast-enhanced MRI
scan within 7 days of SR4554 infusion to provide information on
tumour location and size. Patients received an intravenous (IV)
infusion of SR4554 on day 1 followed by a total of 2–3 MRS studies
over the subsequent 24h. The first MRS study (MRS no. 1) was
performed immediately after the SR4554 infusion; the second
(MRS no. 2) at approximately 16h post infusion and a third (MRS
no. 3) at approximately 20h post infusion if indicated.
Plasma and urine samples were collected over 24h following
SR4554 infusion for pharmacokinetic studies.
Patient eligibility
Inclusion criteria for this study were (1) histologically proven solid
malignancy for which patients were not receiving any anticancer
treatment at the time of study other than cytokine or hormonal
treatments; (2) tumours at least 3cm in size at a site suitable for
19F MRS, that is, at no more than 4-cm depth; (3) age X18 years;
(4) life expectancy of at least 3 months; (5) WHO performance
status p2; (6) no change in corticosteroid requirement during the
2 weeks prior to study entry; (7) adequate haematological
and biochemical function, that is, haemoglobin X9gdl
 1, white
cell count 43.5 10
9l
 1, neutrophil 41.5 10
9l
 1, platelets
X100 10
9l
 1, plasma creatinine o130mmol1
 1, bilirubin
o30mmoll
 1, ALT and AST less than 2.5  the upper limit of
the normal range (ULN) if no known metastatic liver disease, or
less than 5  the ULN for patients with liver metastases; (8)
written informed consent; and (9) agreement to the number of
MRS scans required and ability to comply with this.
Exclusion criteria were (1) treatment with metronidazole at
study entry; (2) radiotherapy during the previous 4 weeks or
chemotherapy during the previous 3 weeks prior to study entry;
(3) pregnant or lactating women; (4) female patients of child-
bearing potential were required to have a negative serum
pregnancy test prior to trial entry, and must have agreed to using
medically approved contraceptive measures during the study and
for 6 months subsequently; male patients must have agreed to
using barrier contraception; (5) major thoracic and/or abdominal
surgery during the previous 3–4 weeks from which the patient had
not yet recovered; (6) patients with implanted or prosthetic
magnetic materials, cardiac pacemakers or other equipment or
aids, which were likely to be disturbed by the magnetic or
radiofrequency fields of the magnetic resonance scanner; (7)
patients with a known history of anaphylactic or anaphylactoid
reaction to any contrast agent, including iodinated agents and
gadolinium complexes; and (8) patients who were at poor medical
risks because of concurrent non-malignant disease.
SR4554 dosage and dose escalation
The initial safety study recommended 1400mgm
 2 as the
maximum tolerated dose (MTD) (Seddon et al, 2003); hence in
this study SR4554 was commenced at this dose level. In order to
generate more reliable localised
19F MRS data, it was decided that
higher doses of SR4554 should be explored following administra-
tion of prophylactic antiemetics in order to maximise
19F detection
by MRS. Three higher doses of SR4554 were studied, 1800, 2200
and 2600mgm
 2. One patient was enrolled into each dose level
provided there was no Xgrade 2 toxicity seen, to a maximum dose
of 2600mgm
 2. If DLT was observed, up to five further patients
would be entered at the dose level below that at which DLT was
seen, to allow evaluation and optimisation of the MRS scanning
protocol.
Owing to the solubility of SR4554, which limited the maximum
dose that could be administered in 1l of 0.9% saline to 5.4g, it was
decided that 2600mgm
 2 would be the maximum dose to be
explored, that is, close to the maximal deliverable dose in a 1 l
volume for a patient with a body surface area of 2.0m
2. It was
considered impractical to administer a diagnostic agent in a
volume in excess of 1l.
In the dose escalation part of the study, patients received
prophylactic antiemetic with a single dose of metoclopramide
(10mg, p.o.) 0.5–1h prior to SR4554 infusion. If the patient
developed nausea or vomiting despite metoclopramide adminis-
tration, granisetron (1mg, p.o.) could be used to treat nausea in
the same patient. For subsequent patients, granisetron (1mg, p.o.,
0.5–1h before SR4554 infusion) could be used as prophylaxis.
If the maximum dose of 2600mgm
 2 was reached without any
patient experiencing DLT, up to 10 patients could then be entered
at this dose level to permit acquisition of localised MRS data.
SR4554 was administered intravenously either over 30 or 60min
(depending on body surface area, hence volume of infusion) as a
single dose on day 1.
SR4554 was diluted with 0.9% normal saline to a total volume of
500 or 1000ml. The drug was supplied by SRI International and
formulated by Cancer Research UK Formulation Unit at the
University of Strathclyde in 0.5ml amber glass ampoules at a
concentration of 200mgml
 1 in 99% dimethyl sulphoxide (DMSO)
and 1% Tween-80.
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Toxicities were graded using the National Cancer Institute
Common Toxicity Criteria version 2.0.
Dose-limiting toxicity was defined as any of the following drug-
related events: sensory or motor neuropathy4grade 1, neutro-
penia4grade 1, neutropenic fever, thrombocytopenia4grade 1,
anaemia4grade 2, any non-haematological toxicity, including
nausea and vomiting,4grade 1, and drug-related death.
Maximum tolerated dose was defined as the dose below that at
which DLT occurred in any patient. Any neurological, haemato-
logical (with the exception of anaemia) or non-haematological
toxicity greater than grade 1, was considered unacceptable for a
diagnostic agent.
Pre-treatment evaluation and follow up
Baseline evaluations (clinical assessment, haematological and
biochemical laboratory tests) were performed within 1 week prior
to patients receiving SR4554 and again on day 1. An electro-
cardiogram and a chest X-ray were performed within 4 weeks of
starting the trial. Patients were then followed up with clinical
assessment, haematological and biochemical laboratory tests
weekly for 4 weeks. Patients who were to receive definitive
treatment (chemotherapy, radiotherapy or surgery) for their
disease were followed up for 2 weeks following SR4554 before
being eligible to receive definitive treatment. Participation in this
study was not allowed to delay a patient’s definitive treatment.
Patients who developed treatment-related toxicities had to be
followed up until all toxicities had returned to baseline.
Plasma pharmacokinetic study
Following SR4554 infusion, patients had plasma samples taken for
analysis of SR4554 concentrations for up to 24h on day 1 only.
Samples were collected before treatment, during infusion, at the
end of infusion, and then at 5, 10 and 60min, and 4, 6, 16, 18, 20
and 24h post infusion. Plasma samples were collected immediately
before and after each MRS study to facilitate a comparison with the
MRS-estimated concentrations of SR4554 in tumour to define the
SR4554 ‘retention index’.
Blood samples (5ml) were collected in heparinised tubes,
centrifuged at 3000r.p.m. (or 1200g)a t4 1C for 5min and
supernatants stored at  701C until analysis. Plasma samples were
extracted and analysed for presence of parent SR4554 by high-
pressure liquid chromatography with UV detection (HPLC-UV), as
previously reported (Aboagye et al, 1995a; Seddon et al, 2002).
Pharmacokinetic data were analysed by non-compartmental
analysis using WinNonLin software version 3.0 (Pharsight
Corporation, Mountain View, CA, USA).
Urinary excretion of SR4554
Urine was collected from each patient, over 24h, immediately after
the start of drug infusion, and total volume was measured and a
10-ml aliquot was stored at  701C until analysis. SR4554 was
extracted from urine samples and measured by HPLC-UV. Samples
were prepared by spiking 250ml of urine with 30ml of internal
standard (50mgml
 1) and adding 250ml of 1% HCl and 1ml of
ethyl acetate. After centrifugation for 5min at 5000r.p.m., the
organic phase was removed and dried, and the residue was
dissolved in 150ml of methanol. Samples were then analysed for
concentration of SR4554 as for plasma.
Magnetic resonance spectroscopic studies
Magnetic resonance spectroscopic studies were performed using
a 5, 10 or 16cm dual-resonant
1H/
19F transmit/receive surface
coil and a 1.5T MR system (Siemens Vision, Erlangen, Germany).
Surface coils were built in the mechanical workshop at The Institute
of Cancer Research. Transverse, sagittal and coronal localiser MR
images were acquired using a TruFisp sequence (repetition time
(TR)¼6.3ms; TE¼3.0ms). Magnetic resonance spectra localised
only by the sensitivity profile of the RF surface coils (‘unlocalised’)
were acquired in blocks of 512 scans using a 1.28ms adiabatic
radiofrequency pulse, and a repetition time (TR) of 1s. The adiabatic
pulse was used to ensure uniform signal excitation by the surface
coil. Reference
1H spectra were acquired from tissue water using the
same coil and sequence for use in subsequent SR4554 concentration
calculations. Since water is present at high concentration, only eight
scans were required for this. A longer TR (5s) was used to remove
the need to correct for saturation effects in the water spectra. If 512
scans of the unlocalised data did not show a clear
19F resonance
peak, further unlocalised measurements were acquired to improve
the signal-to-noise ratio (SNR); otherwise
19F spectroscopic images
were acquired. Spectroscopic images used a grid size appropriate to
the tumour, 8 8 8 phase-encoding steps, two scans per phase-
encode, TR¼1s and the same adiabatic pulse as for the unlocalised
measurements. It was not possible to also acquire
1H spectroscopic
images, to be able to restrict the total examination time to an
acceptable length. Spectral data were processed by apodisation,
Fourier transformation, phase correction and peak integration. Peak
integration was performed using the ‘Luise’ software supplied on the
scanner (Siemens, Erlangen, Germany), which performs a best fit to
the peak and baseline assuming a Lorentzian line shape.
Three parameters were calculated from the spectral data. The
first was SNR (defined as peak height divided by peak-to-peak
noise), used as an indicator of whether there was detectable
19F
signal in the spectrum. Peaks were regarded as significant if
SNR41. The second parameter was the
19F-RI, defined as the ratio
of the
19F signal measured at the second or third time point,
relative to that measured at the first time point, where in each case
the
19F signal was normalised by the signal from tissue water. This
method has been previously validated in mouse model studies
(Seddon et al, 2002). Finally we used the data from the unlocalised
measurements to estimate the average SR4554 concentration in
tissue (Payne et al, 2005). This is possible since the same surface
coil was used for both
19F and
1H measurements, giving the same
spatial sensitivity distribution for both measurements. At the
second and third time points it is anticipated that SR4554 will
only be retained in the regions of hypoxic tissues (i.e., part of the
tumour) so that the average concentration over the sensitive region
of the coil is much less than the actual concentration in the
hypoxic regions. It is expected that SR4554 will be taken up into all
tissues except fat, so only the water component of the
1H spectra
was used in the calculation as follows:
½SR4554 ¼
19FSR4554peakarea
1Hwaterpeakarea
 
Nð1HÞ
Nð19FÞ
 ð55 106Þ 0:75 GF SFð19FÞ
;
where [SR4554] is the concentration of SR4554 (mM), N(
1H) is the
number of
1Ha t o m si nH 2O(¼2), N(
19F) is the number of
19Fa t o m s
in SR4554 (¼3), 55 10
6 is the concentration of pure water (in mM),
0.75 is the assumed water content of tissue and GF accounts for the
difference in receiver gain used for the large water signal and small
19F signals. The final term, SF, is the
19F saturation factor and
accounts for partial saturation of the signal expected from the shorter
repetition time used in the
19F measurements, and is given by:
SFð19FÞ¼
1
1   e ðTR=T1Þ
The T1 used was that measured at the same field strength in a pellet
of liver microsomes containing SR4554.
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after infusion of SR4554. The second study (MRS no. 2) was
performed 16h post infusion. The choice of 16h was based on the
estimated time to virtually complete the elimination of SR4554
from plasma, that is, approximately five times the plasma
elimination half-life of 3.5h. At this time any significant signal
would indicate retention of SR4554 bioreduction products
indicative of hypoxia. In preclinical studies the optimal time point
for calculating the
19F-RI was found to be 3h, that is,
approximately 5 T1/2 in mouse (T1/2¼37min; Seddon et al,
2002). If a significant
19F signal was detected in MRS no. 2, a third
MRS study (MRS no. 3) was performed between 18 and 20h post
infusion.
The position of the surface coil at the first MRS study for each
patient was noted carefully to enable reproducible positioning for
subsequent scans.
RESULTS
Patient characteristics
A total of 26 patients with a variety of malignancies were enrolled
between July 2003 and October 2005. Patient characteristics are
shown in Table 1a. Most patients had gastrointestinal stromal
tumour (GIST), head and neck cancer or melanoma. Other tumour
types included sarcomas; fibromatosis; and cancers of the
stomach, oesophagus and biliary tract. It was decided to include
patients with a wide variety of tumour types in order to establish
an MTD for SR4554 quickly, as there were recruitment difficulties
in the study.
The median age of patients was 55 years (range 21–83). Four
dose levels of SR4554 were investigated: 1400 (n¼16), 1800
(n¼1), 2200 and (n¼1) 2600mgm
 2 (n¼8).
Table 1b presents a summary of patients who experienced
toxicity and the dose level of SR4554 they received.
Dose escalation and toxicity
The most common side effects were nausea and/or vomiting, and
headache. None of these were dose-limiting (Table 1b). Grade 1
nausea and/or vomiting was observed in three patients. In two of
these the event could be attributed partially to morphine
administered for tumour pain before commencement of their
SR4554 infusion. In one patient, however, vomiting was clearly
related to SR4554. Her symptoms resolved upon termination of
SR4554 infusion. None of these three patients had to receive
granisetron, however.
One patient experienced a grade 1 itch around his neck within
2h of SR4554 infusion, which was considered possibly drug-
related, which resolved within 24h.
A mild headache (grade 1) was observed in five patients. In all of
these patients, the symptom appeared within 13h of SR4554
infusion, and was mild in all the cases. It resolved within 24h of
infusion and did not recur. Two of these patients were later found
to have brain metastasis 3 and 4 months later, respectively, but
given the temporal relationship with SR4554 this symptom was
considered possibly drug-related.
One patient experienced alteration in taste sensation within
minutes of the start of SR4554 infusion. This was of no clinical
significance and was almost certainly due to the DMSO component
of the infusion.
No other toxicities were seen. During the follow-up period, we
did not observe any haematological or biochemical alterations on
blood tests or urinalysis.
Plasma pharmacokinetic studies
Twenty-five patients underwent plasma sampling for pharmaco-
kinetic studies (Table 2). Only one patient was treated at each of
dose levels 1800 and 2200mgm
 2; therefore there are no mean
values for these dose levels. SR4554 showed a high volume of
distribution (mean±s.d.: 34.6±14.7l) and a short terminal half-
life (3.7±0.9h). This distribution, together with the high excretion
of parent drug described below, resulted in high plasma clearance
(9.8±4.2lh
 1). As expected, the peak concentration of SR4554
(Tmax) was observed at the end of infusion, that is, at either 30 or
60min. Peak plasma concentration (Cmax) was 110.2±50.9mgl
 1,
and the area under the concentration–time curve to last measured
time point (AUClast) was 415.4±235.7hr*mgl
 1.
Some variability was observed in the overall pharmacokinetic
parameters between dose levels. The mean plasma half-life varied
from 3.1 to 3.8h depending on the dose level, the mean volume of
distribution of drug was between 27 and 45l, and mean plasma
clearance was between 7.7 and 12.7lh
 1.
Based on the narrow dose range studied and limited data at 1800
and 2200mgm
 2, it was difficult to draw conclusions regarding
Table 1a Patient characteristics
(n¼26)
Characteristics n %
Age (years)
Median 55
Range 21–83
Sex
Male 16 61.5
Female 10 38.5
WHO performance status
0 4 15.4
1 22 84.6
Tumour type
Gastrointestinal stromal
Tumour (GIST) 9 34.6
Head and neck (SCC) 5 19.2
Melanoma 5 19.2
Sarcoma 2 7.7
Fibromatosis 2 7.7
Gastric (adenocarcinoma) 1 3.8
Oesophageal (adenocarcinoma) 1 3.8
Biliary tract (adenocarcinoma) 1 3.8
Abbreviations: GIST¼gastrointestinal stromal tumour; SCC¼squamous cell carci-
noma.
Table 1b Drug-related toxicities: headache (n¼5), nausea/vomiting
(n¼3), itch (n¼1) and altered taste (n¼1)
Patient
SR4554 dose level
(mgm
 2) Toxicity Grade
12 1400 Itch 1
16 1400 Vomiting 1
19 1400 Nausea 1
25 1800 Headache 1
26 2200 Headache 1
27 2600 Headache 1
28 2600 Nausea, vomiting 1
29 2600 Headache 1
30 2600 Alteration in taste sensation 1
33 2600 Headache 1
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clearance was not significantly different at 1400mg when
compared with 2600mg SR4554 (Table 2).
Urinary excretion studies
Twenty-four-hour urine collection samples were analysed for
SR4554 in order to calculate the percentage of unchanged SR4554
excreted in 24h. The average percentage urinary excretion of
SR4554 for all dose levels was 47±17%. There was a significant
difference between the percentage of SR4554 excreted after the
administration of 1400 and 2600mg (58.6±4.9% vs 37.3±5.9%,
unpaired t-test with Welch’s correction Po0.01).
Relationship between creatinine clearance and SR4554
plasma clearance
To explore the possibility that differences in patients’ renal
function could account for some of the variability in plasma
clearance or percentage drug excreted, we performed a linear
regression analysis of creatinine clearance against drug plasma
clearance and percentage drug excreted. This showed a modest
correlation (r
2¼0.38, P¼0.002) between creatinine clearance and
drug plasma clearance, but a non-significant correlation between
creatinine clearance and percentage drug excreted in urine
(r
2¼0.04, P¼0.39).
Magnetic resonance spectroscopic studies
A total of 24 patients underwent 2–3 MRS studies following
SR4554 infusion. MRS no. 1 and MRS no. 2 were performed at the
mean time points of 1.1±0.2 and 16.0±0.4h, respectively, post
infusion (Supplementary Table 5). Two patients (patients 28 and 29)
underwent MRS no. 2 at B12h post infusion to examine the
feasibility of performing localised studies and the probability of
obtaining a
19F signal on these localised studies. Only unlocalised
MRS studies were performed at the first two time points, that is,
immediately after infusion and at 12h; for patient 28, however, the
first MRS study was performed at 4.9h post infusion due to
development of some medical complications, which prevented her
from undergoing the study immediately after infusion. Only a
small
19F signal was observed on this patient’s MRS no. 1 study,
with an SNR of 3.6, whereas on MRS no. 2 there was no significant
19F signal detected (SNR was 1.0). For patient 29, the SNR on MRS
no. 1 performed 0.9h post infusion was 17.7; this decreased
significantly to 1.5 on MRS no. 2 performed at 11.7h post infusion
(Supplementary Table 5).
Unlocalised MRS no. 3 was performed only for seven patients
(whose unlocalised MRS no. 2 showed adequate
19F signal to
proceed to MRS no. 3), at a mean time point of 19.9±0.7h post
infusion (Supplementary Table 5). A strong
19F signal was present
in the unlocalised MRS no. 1 studies of all 22 patients as expected,
due to the presence of parent SR4554, with a mean SNR of 28.9
(range 3.6–152; excluding patients 28 and 29 who underwent MRS
no. 2 at B12h post infusion). At MRS no. 2 a
19F signal was
present in the unlocalised spectra of 16 of 22 patients, with a mean
SNR of 3.1 (range 0.3–10.0), whereas the mean SNR of the detected
peaks in unlocalised MRS no. 3 spectra was 3.5 (range 1.8–5.0).
Examples of MRS spectra are provided in Figure 1.
Localised MRS studies were performed using spectroscopic
imaging for nine patients at the first time point (Table 3). Seven of
these patients underwent further localised MRS studies at B16h
post infusion (localised MRS no. 2), while two of these patients
(patients 28 and 29) had MRS no. 2 at B12h. Five of these nine
patients underwent localised MRS at B20h post infusion
(localised MRS no. 3). Localised MRS no. 1 was performed at a
mean time point of 1.4h post infusion. A significant SNR
(SNR41.0) was seen for all seven patients, giving a mean SNR
of 6.2 (Table 3). Among patients who had localised MRS no. 2 at
B16h (performed at a mean time point of 16.4h post infusion), a
significant SNR was seen in five of seven patients, with a mean
SNR of 1.7. On localised MRS no. 3, a significant SNR was seen in
four of five patients, with a mean SNR of 1.5.
Sixteen patients received a dose of 1400mgm
 2. The calculated
average tissue concentration of SR4554 from unlocalised measure-
ments at MRS no. 1 in this group was 122±33mM, as compared
with 220±135mM in plasma.
Evidence for
19F retention
Figure 2 and Table 4 show the SR4554 retention index in tissue
calculated using
19F MRS, and the equivalent parameter measured in
plasma samples acquired before and after each MRS measurement.
Comparison of the 16-h retention indices based on MRS-estimated
concentrations of SR4554 (mean 13.6, range 0.6–43.7) and plasma
pharmacokinetic measurements of SR4554 (mean 4.1, range 0.6–7.3)
showed significant
19F retention in tumour as detected by MRS
(P¼0.001, paired Student’s t-test, one-sided; Table 4). This
discrepancy between MRS-derived
19F-RI and plasma-derived
retention index could be attributed to the presence of bioreduced
SR4554 in tumour indicating possible presence of hypoxia.
Seven patients underwent unlocalised MRS no. 3 at (mean±s.d.)
19.9±0.7h (Supplementary Table 5). The dose levels of SR4554
received were 1400 (n¼1), 2200 (n¼1) and 2600 (n¼5). A mean
SNR of 3.5 (range 1.8–5.0) was obtained. At this time point, which
is equivalent to approximately six times the plasma elimination
half-life of SR4554, o1.6% of parent SR4554 would have remained
in the tumour vasculature.
The localised MRS studies of five patients performed at B20h
post infusion yielded a mean SNR of 1.5 (range 1.0–1.8; Table 3),
which is more specifically indicative of
19F retention in tumour.
DISCUSSION
SR4554 is a 2-nitroimidazole that was rationally designed to
function as a biomarker of hypoxia detectable by MRS (Aboagye
et al, 1995b, 1997a,b, 1998a,b). A pilot study demonstrated that it
Table 2 Mean values (±s.d.) of plasma pharmacokinetic parameters and % excreted in urine at various SR4554 dose levels
Dose level
(mgm
 2) No. of patients Tmax (h) Cmax (mgl
 1) AUClast (h*mgl
 1) T1/2 (h) Vss (l) Cl (lh
 1) % excreted
1400 15 0.9±0.3 98±49
a 310±160
a 3.8±0.9 37±17 10.5±4.7
b 58.6±4.9
1800 1 1.0 74 308 3.1 45 12.7 43
2200 1 1.2 85 291 3.2 38 12.7 35
2600 8 1.0±0.1 141±49
a 641±231
a 3.7±1.0 27±6 7.7±2.7
b 37.3±5.9
Abbreviation: AUC¼area under the curve.
aComparison of patients treated at dose levels 1400 and 2600mgm
 2 showed significant correlation both between dose level and
AUC (P¼0.0006), and between dose level and Cmax (P¼0.05; unpaired Student’s t-test, two-sided). Patients treated at the intermediate dose levels of 1800 and 2200mgm
 2
were not included in this analysis as only one patient was treated at each of these dose levels.
bNo statistically significant difference in plasma clearance was observed between the
1400 and 2600mgm
 2 groups of patients (P¼0.14; unpaired Student’s t-test, two-sided).
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sTable 3 Localised MRS studies, times post-infusion and corresponding SNRs for patients who underwent localised studies at X2 scanning time points
(n¼9)
MRS no. 1 MRS no. 2 MRS no. 3
Patient
Time of study
post infusion (h) SNR
Time of study
post infusion (h) SNR
Time of study
post infusion (h) SNR
23 1.2 3.2 16.0 1.0 — —
26 1.0 9.2 16.0 1.0 — —
28 5.1 2.3 12.2 0.8 — —
29 1.1 4.9 12.1 1.0 — —
30 1.8 2.3 16.4 1.4 19.7 1.8
31 1.7 12.8 16.6 2.7 20.0 1.7
32 1.2 7.2 16.5 1.6 20.7 1.5
33 1.4 3.5 16.5 1.4 20.8 1.4
34 1.3 5.0 16.9 2.8 21.3 1.0
Mean
a 1.4 6.2 16.4 1.7 20.5 1.5
Range 1.0–1.8 2.3–12.8 16.0–16.9 1.0–2.8 19.7–21.3 1.0–1.8
No. of patients with SNR41.0 9 5 4
Abbreviations: MRS¼magnetic resonance spectroscopy; SNR¼signal-to-noise ratio. SNR values 41.0 on MRS no. 2 or MRS no. 3 (highlighted) are considered significant and
indicative of the presence of hypoxia.
aExcluding patients 28 and 29 who had MRS no. 2 at B12h post infusion.
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Figure 1 Unlocalised and localised MRS spectra of patient 30. Unlocalised MRS spectra acquired from patient 30 (GIST measuring 62 60 55mm) at
(A) 1.4h; (B) 16.1h and (C) 19.4h following the end of the SR4554 infusion (2600mgm
 2). Localised MRS spectra were acquired at (D) 1.8h; (E) 16.4h
and (F) 19.7h following the end of the infusion. In the localised studies, the images in each panel in panels D–F show different views of the tumour studied,
and the highlighted volume (voxel) in each image shows the part of the tumour from where the MRS spectrum was acquired. The timings of B16 and
B20h post infusion (at the time of MRS no. 2 and MRS no. 3 respectively) are equivalent to approximately 5.5  and 6.5  the half-life of SR4554 in this
patient, respectively.
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scould be administered by IV infusion without toxicity at a dose
of 1400mgm
 2, above which nausea and vomiting were potentially
dose-limiting, at least without prophylactic antiemetics.
Preliminary evidence of fluorine retention in tumour was
observed, indicative of bioreduction of SR4554 in the presence of
hypoxia (Seddon et al, 2003).
We now report results of a further 26 patients. In this part of the
study, further patients were treated at 1400mgm
 2, which was
found to be very well-tolerated. Unlocalised MRS studies at this
dose level showed some evidence of
19F retention suggestive, based
on animal model data, of tumour hypoxia, but
19F signals detected
were generally small. At higher doses of SR4554 (1800–
2600mgm
 2) administered with prophylactic antiemetics, we
observed a higher rate of
19F signal detection on both unlocalised
and localised MRS studies. As discussed above, any
19F signal
detected at the time of MRS no. 2 can reasonably be attributed to
the presence of bioreduction products, since this study was
performed at a time when the concentration of parent compound
in plasma would have been only around 3% of Cmax (5  plasma
elimination T1/2). Another way of looking at this is the SNR. A
mean SNR of 3.5 (Supplementary Table 5) is significant for
presence of bioreduction products.
Comparison of the 16-h
19F-RI provided by MRS with the
retention index from plasma pharmacokinetic studies also showed
clear evidence of
19F retention, particularly in patients for whom
localised MRS studies were performed. The mean
19F-RI was 13.6,
as compared with a mean plasma retention index of only 4.1
(Table 4). The mean ratio of MRS-derived to plasma-derived
retention index was 4.8 (range 0.9–18.8) and the ratio was greater
than 1 in all but 2 of 16 patients (Table 4). Furthermore, the
demonstration of
19F signal, albeit of relatively small magnitude, in
the 20-h localised MRS study of 4 of 5 patients (Table 3) strongly
suggests
19F retention, since at this time point an even larger
proportion (498.4%) of parent drug should have been ‘washed
out’ and thus any
19F signal detected would be likely to originate
from bioreduced and bound products of SR4554 in hypoxic cells.
Pharmacokinetic analyses of SR4554 in this study showed results
consistent with previously reported data (Seddon et al, 2003).
SR4554 has been shown to have a short plasma half-life of
3.7±0.9h, a high plasma clearance of 9.8±4.2lh
 1 and relatively
high urinary excretion, ensuring rapid elimination of unmetabo-
lised parent compound so that only
19F signals from bioreduced
products in hypoxic cells are detected by MRS studies performed
at the appropriate time. Preclinical studies of SR4554 demon-
strated a clear relationship between tumour concentration (AUC)
and plasma AUC. Plasma AUC and Cmax increased from 1400 to
2600mgm
 2 in this study, as expected from the greater
19F signal
detected at higher doses. For example, of the seven patients who
underwent MRS no. 3, six received higher doses of SR4554, 2200
(n¼1) and 2600mgm
 2 (n¼5), indicating greater
19F retention.
Clearly the dose of SR4554 needs to be enough to ensure
penetration into tumour to allow sufficient intracellular bioreduc-
tion and binding to permit
19F quantitation by MRS (Brown and
Workman, 1980; Workman and Brown, 1981; Aboagye et al, 1996).
The modest correlation of creatinine clearance with plasma
clearance is consistent with renal excretion of SR4554 by
glomerular filtration.
Central nervous toxicities such as disorientation and confusion
commonly observed with other nitroimidazoles were not seen in
our study, although a very small number of patients experienced
grade 1 nausea and vomiting. However, grade 1 headache was
observed in five patients shortly after treatment with higher doses
of SR4554 (X1800mgm
 2), which was probably drug-related.
Central nervous system penetration was not predicted by
preclinical data (Aboagye et al, 1995b), which indicated that
SR4554 behaves as a hydrophilic agent despite its relatively high
octanol:water partition coefficient of 0.65, which was attributed to
the hydrophilic character of the side chain (Aboagye et al, 1996).
Similarly, the pharmacokinetic data are consistent with a
hydrophilic drug. Apart from the low incidence of mild nausea/
vomiting and headache, SR4554 was found to be well-tolerated
even when administered at high doses with prophylactic anti-
emetics, and hence from these aspects is suitable for use as a
diagnostic agent.
In this study, we have not performed correlative studies to
confirm the presence of hypoxia as detected by
19F MRS. However,
Table 4 MRS-derived and plasma-derived retention indices at 16h
Patient
Plasma-derived
retention index
(RI) at 16h
a
MRS-derived
retention
index (RI)
at 16h
b
Ratio of
MRS-derived RI
to plasma-derived RI
9 2.8 14.4 5.1
11 7.3 9.1 1.3
12 2.9 13.5 4.7
14 3.6 14.0 3.9
15 5.8 21.1 3.6
16 0.6 0.6 0.9
18 1.5 4.7 3.2
20 3.1 2.6 0.9
23 1.6 11.5 7.2
25 2.9 17.3 6.1
26 3.3 18.1 5.6
30 2.8 21.3 7.6
31 4.1 8.1 2.0
32 4.2 16.4 3.9
33 2.3 43.7 18.8
34 3.4 7.4 2.2
Mean 4.1 13.6 4.8
Range 0.6–7.3 0.6–43.7 0.9–18.8
Abbreviation: MRS¼magnetic resonance spectroscopy. MRS-derived
19F-RI at 16h
plotted against plasma-derived retention index for patients for whom there are
complete data sets for these time points (n¼16).
aPlasma-derived retention
index¼Ratio of plasma SR4554 concentration at the time of MRS no. 2 to its
concentration at the time of MRS no. 1 (plasma SR4554 concentration measured by
HPLC).
bMRS-derived
19F-RI¼Ratio of SR4554 concentration estimated by MRS
no. 2 to its concentration estimated by MRS no. 1.
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Figure 2
19F retention index at 16h, estimated by MRS, as compared
with SR4554 retention index calculated from plasma by HPLC (n¼16).
The diagonal line represents the line of unity (which indicates there is no
difference between plasma retention index and MRS retention index). Only
one
19F-RI (0.45) value lies to the right of the line of unity; this is patient 29
who had MRS no. 2 at 11.7h, and, therefore, was not expected to show a
significant
19F-RI at this early time point as this is equivalent to only 3.2 T1/2
of SR4554 when the concentration of SR4554 in plasma would exceed its
concentration in tumour.
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sthe next step would be to correlate results obtained from
19F MRS
with another method of assessing tumour hypoxia, such as the
Eppendorf oxygen electrode or immunohistochemical methods
using another nitroimidazole such as pimonidazole. Other hypoxia
markers that may be useful for correlative studies with SR4554
include ‘endogenous’ markers of hypoxia, such as HIF-1a, CA-9
and GLUT-1, which are upregulated under hypoxic conditions and
which can be detected by immunohistochemistry (Vordermark
and Brown, 2003). The ultimate evidence for the usefulness of
19F
MRS as a measure of hypoxia would be to demonstrate its role in
predicting patient or treatment outcome, as has been demon-
strated with oxygen electrodes in several clinical studies (Brizel
et al, 1996, 1999; Hockel et al, 1996; Nordsmark et al, 1996, 2001;
Fyles et al, 1998; Stadler et al, 1999; Rudat et al, 2000).
On a case-by-case basis, it is possible that the non-observability
of a
19F signal in tumour could be due to other tumour-specific
factors rather than lack of hypoxia. For example, there are factors
at the cellular and biochemical level, such as concentration of the
parent nitroimidazole (Chapman et al, 1983), temperature
(Stratford and Adams, 1977) and the type of nitroreductase
enzymes involved (Workman, 1992; Joseph et al, 1994), which
contribute to the process of nitroimidazole bioreduction and thus
generation of a
19F signal on MRS. These factors, which may differ
significantly in different tumours and individuals, could alter the
binding of nitroimidazoles.
In this study, a
19F signal was observed at 16h in patients with
the following tumour types: GIST (n¼9), melanoma (n¼4),
sarcoma (n¼2), fibromatosis (n¼1) and head and neck SCC
(n¼1) (Supplementary Table 5). On the other hand, there were
three patients with head and neck SCC whose MRS no. 2 did not
show a
19F signal, in contrast to what one might have expected
from the known hypoxic tendency of such tumours (Supplemen-
tary Table 5). It is difficult to draw conclusions regarding the
correlation between the presence of a
19F signal and the histology
of the tumour as there are several other factors, which would have
contributed to the observation of a
19F signal, such as the size and
depth of the tumour.
Despite the feasibility and safety of SR4554 as a hypoxia marker
as demonstrated in this study, the magnitude and rate of
19F
detection on localised MRS studies was relatively low despite using
higher doses of SR4554. This reflects the inherently low sensitivity
of MRS as compared with positron-emission tomography (PET),
for example. There is little scope to enhance the sensitivity of
19F
detection using MRS by further escalating the dose of SR4554 due
to solubility limitations. The maximum permitted concentration
when diluted in 0.9% saline is 5.4mgml
 1. Doses in excess of
2600mgm
 2 would need to be administered in volumes 41l,
which would require infusion times of longer than the 1-h duration
used in this study, and which would be inconvenient and
potentially harmful in terms of acute fluid load. Other strategies
to improve the sensitivity of detection include use of a higher
magnetic field strength, for example, 3.0T, or to increase the
number of
19F atoms in the SR4554 molecule. To develop SR4554
further as a hypoxia marker, the most practical next step would be
to use a more powerful MR scanner.
Positron-emission tomographic imaging has been investigated
as a technique for detecting hypoxia. Several clinical studies
have been performed to date, which demonstrated the usefulness
of pretreatment
18F-fluoromisonidazole in predicting patient
prognosis or treatment outcome (Eschmann et al, 2005; Rajendran
et al, 2006; Rischin et al, 2006). Thus, another possible future
development of SR4554 as a hypoxia marker, would be to label the
molecule with
18F, to enable detection by both
19F MRS and
18F
PET, thus enabling a comparison of retention and hypoxia
estimation between the two techniques. This would require a
combined PET–MRI scanner, allowing simultaneous acquisition
of data from both modalities. The advantage of this is that the
intrinsic differences between the two techniques could serve to
complement each other in, for example, the sensitivity of detection
and spatial resolution. Recent studies have already shown the
feasibility of simultaneous PET–MRI imaging in small-animal
studies and in humans, although none of these involved hypoxia
imaging (Catana et al, 2008; Schlemmer et al, 2008). Thus, a
possible step would be to correlate MRS measurements with
18F
PET measurements, particularly given recent data on the
predictive value of
18F PET (Eschmann et al, 2005; Rajendran
et al, 2006; Rischin et al, 2006).
There have been recent reports of alternative fluorine-contain-
ing nitroimidazoles designed for MRS hypoxia detection
(Papadopoulou et al, 2006; Procissi et al, 2007). One of these is
2-nitro-a[(2,2,2-trifluoroethoxy)methyl]-imidazole-1-ethanol,
(TF-MISO), an analogue of misonidazole, with chemical properties
consistent with a hypoxia marker, which has been shown in
preclinical studies to show promise as an MR hypoxia marker
(Procissi et al, 2007). It would be very interesting to study this
compound using MRS in human tumours.
In summary, the results from this study have confirmed the proof
of principle for tumour retention of SR4554 using
19F MRS and
demonstrated the feasibility of this approach that has potential as a
non-invasive method of detecting tumour hypoxia. Retention of the
agent in many tumours is consistent with hypoxia-mediated
bioreduction. The next step would be to correlate results from
19F
MRS with those from an alternative and accepted method of measuring
tumour hypoxia. Further refinements could involve the use of a higher
magnetic field strength to increase the sensitivity of detection, or to
increase the number of
19F atoms in SR4554, or use of simultaneous
PET–MRI imaging with a suitably labelled probe molecule.
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